Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3272247 | Journal de Gynécologie Obstétrique et Biologie de la Reproduction | 2015 | 8 Pages |
Abstract
Tocolytic agents have limited efficacy, delaying preterm delivery by 48Â hours to 7Â days, without any neonatal benefit. Cyclo-oxygenase inhibitors and calcium canal inhibitors seem to be the most efficient. Betamimetics are tocolytic agents with the highest incidence of severe maternal side effects. Oxytocin receptors antagonists and cyclo-oxygenase inhibitors are tocolytic agents with the best maternal tolerating profile. Nifedipin is the tocolytic agent presenting the best fetal tolerating profile. However, doubts persist on fetal and neonatal tolerance for cyclo-oxygenase inhibitors and probably even for oxytocin receptors antagonists. A combined or sequential tocolytic treatment did not prove superior to a single tocolytic treatment although the former is also associated with a high incidence of severe adverse maternal effects. Nevertheless, this low efficiency should not make us forget their major interest in case of premature labour: to allow the mother's in utero transfer to a level II or III maternity following the gestational age, and moreover to gain time so as to obtain an optimal interval for the fetal lung maturation by corticoid injection. Tocolytic agents should be used between 24+0Â and 34+6Â weeks of amenorrhea. They should be used on the short term (24Â to 72Â hours) owing to their short period of efficacy and to the risk of side effects that increases with the duration of use.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
P. Rozenberg,